ANTI-INFECTIVE + NSAID COMBOS​

VIGOQUIN-KT | Ketorolac Tromethamine & Moxifloxacin Opthalmic Solution

Product Description:

COMPOSITION

Moxifloxacin Hydrochloride IP

Eq. to Moxifloxacin……………………………………………..0.5% w/v

Ketorolac Tromethamine IP…………………………………0.4% w/v

Aqueous Buffered Vehicles………………………………….q.s.

(Solution preserve with Ionic Buffer System)

DESCRIPTION

Vigoquin-KT is a combination topical ophthalmic preparation containing Moxifloxacin Hydrochloride 0.5% and Ketorolac Trometthamine 0.5%.

Moxifloxacin is an 8-methoxy fluoroquinolone anti-infective with a diazabicyclononyl ring at the C7 position.

Ketorolac is a member of the pyrrolopyrrole group of non-steroidal anti-inflammatory drugs (NSAIDs)

CLINICAL PHARMACOLOGY

Microbiology: The antibacterial action of Moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action for quinolones, including Moxifloxacin, is different from that of macrolides, aminoglycosides or tetracyclines. Therefore, Moxifloxacin may be active against pathogens that are resistant to these antibiotics. There is no cross-resistance between Moxifloxacin and the aforementioned classes of antibiotics. Cross-resistant has been observed between systemic Moxifloxacin and some other quinolones, In vitro resistance to Moxifloxacin develops via multiple-step mutations. Moxifloxacin has been shown to be active against most strains of the following microorganisms.

Aerobic Gram-Positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureu, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneunomiae, Streptococcus viridans group

Aerobic Gram-Negative microorganisms: Acinetobacter iwoffii, Haemophilus influenzae, Haemophilus parainfluenzae.

Other microorganisms

Chlamydia trachomatis

The following in vitro data are also available, but their clinical significance in ophthalmic infections is known. The list of organisms is provided as guidance only in assessing the potential treatment of conjunctival infections. Moxifloxacin exhibits in vitro minimal inhibitory concentrations (MICs) of 2µg/ml or less (systemic susceptible breakpoint) against most (=90%) of strains of the following ocular pathogens.

Aerobic Gram-Positive microorganisms: Streptococcus pyogenes

Aerobic Gram-Negative microorganisms: Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Moraxxella catarrhalis, Proteus mirabilis.

Aerobic microorganisms: Fusobacterium species, Prevotella species.

Ketorolac Tromethamine is a non-steroidal anti-inflammatory drugs which, when administered systemically, has demonstrated analgesic. Anti-inflammatory and antipyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. 

ENQUIRY FORM

Enquiry Form